Novel Benzimidazol-2-Acetamide Derivatives as Submicromolar Casein Kinase 1δ Inhibitors with Favourable Predicted Drug-like Properties.
5 affiliations
- 1Section of Pharmaceutical and Nutraceutical Sciences, Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Via Ugo Schiff, 6, 50019 Sesto Fiorentino, Italy.
- 2Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127 Trieste, Italy.
- 3Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy.
- 4European Laboratory for Non-Linear Spectroscopy (LENS), University of Florence, Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy.
- 5National Institute of Optics-National Research Council (CNR-INO), Via Nello Carrara 1, 50019 Sesto Fiorentino, Italy.
Abstract
Background/Objective: Casein kinase 1δ (CK1δ) plays a central role in regulating circadian rhythms, DNA repair, apoptosis, and cell proliferation, and its dysregulation is associated with both cancer and neurodegenerative diseases, making CK1δ an attractive therapeutic target. This study aimed to develop novel CK1δ inhibitors with favourable drug-like properties through the synthesis and biological evaluation of benzimidazol-2-acetamide derivatives. Methods: A novel series of benzimidazol-2-acetamide derivatives was synthesized, incorporating different substituents on the benzimidazole core (5-chloro, 5,6-dichloro, 5-nitro, and 5-cyano) and various saturated cyclic amines on the acetamide moiety. Compounds were evaluated for CK1δ inhibitory activity, while molecular docking and molecular dynamics simulations were performed to investigate their binding mode. In silico ADME predictions assessed pharmacokinetic properties, and cytotoxicity was evaluated in SH-SY5Y neuroblastoma cells. Results: The 5,6-dichloro derivatives 20 and 24, bearing piperidin-4-ylmethanamine and morpholine moieties, respectively, displayed the highest CK1δ inhibitory activity (IC₅₀ = 0.172 and 0.223 μM). The 5-cyano analogue 22 also exhibited a good potency (IC₅₀ = 0.224 μM). Computational studies confirmed an ATP-competitive binding mode and highlighted the dynamic behaviour of the solvent-exposed substituents within the CK1δ binding site. Predicted pharmacokinetic properties suggested favourable oral absorption and blood-brain barrier penetration. Compounds 20, 22, and 24 showed no cytotoxicity in SH-SY5Y cells at concentrations up to 10 μM. Conclusions: The new benzimidazol-2-acetamide derivatives exhibited good inhibitor activity against CK1δ, favourable predicted ADME properties, and low cellular toxicity. The combined experimental and computational findings provide valuable insights for the further optimization of this scaffold toward the development of therapeutics for CK1δ-related diseases.
Related
- Design, Synthesis, In Vitro and In Silico Evaluation of Triazole–Benzimidazole Hybrid Derivatives as Potential Inhibitors of EGFR, EGFR-L858R, and EGFR-L858R/T790M
- New N -pyridinyl(methyl)-indole-2- and 3-(Alkyl)carboxamides and Derivatives Acting as Systemic and Topical Inflammation Inhibitors
- Synthesis, in silico study and cytotoxic evaluation of new benzimidazole derivatives as potential aromatase inhibitors
- Isatin derivatives as potent cholinesterase inhibitors: recent developments and future challenges
- Synthesis and Evaluation of Aryloxy-Acetamide Derivatives as CBX2 Inhibitors
BibTeX
@article{ceni2026novel,
title = {{Novel Benzimidazol-2-Acetamide Derivatives as Submicromolar Casein Kinase 1δ Inhibitors with Favourable Predicted Drug-like Properties.}},
author = {Costanza Ceni and Sara Calenda and Giulia Vagnoni and Elisa Marinari and Daniela Catarzi and Flavia Varano and Letizia Trevisan and Michelle Fornasier and Stephanie Federico and Giampiero Spalluto and Gianluca Novello and Veronica Salmaso and Stefano Moro and Martino Calamai and Vittoria Colotta},
journal = {Pharmaceuticals (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/ph19101666},
url = {https://europepmc.org/article/MED/42943363},
note = {CC BY},
}
RIS
TY - JOUR
TI - Novel Benzimidazol-2-Acetamide Derivatives as Submicromolar Casein Kinase 1δ Inhibitors with Favourable Predicted Drug-like Properties.
AU - Costanza Ceni
AU - Sara Calenda
AU - Giulia Vagnoni
AU - Elisa Marinari
AU - Daniela Catarzi
AU - Flavia Varano
AU - Letizia Trevisan
AU - Michelle Fornasier
AU - Stephanie Federico
AU - Giampiero Spalluto
AU - Gianluca Novello
AU - Veronica Salmaso
AU - Stefano Moro
AU - Martino Calamai
AU - Vittoria Colotta
PY - 2026
DA - 2026/10/21
JO - Pharmaceuticals (Basel, Switzerland)
DO - 10.3390/ph19101666
UR - https://europepmc.org/article/MED/42943363
AB - Background/Objective: Casein kinase 1δ (CK1δ) plays a central role in regulating circadian rhythms, DNA repair, apoptosis, and cell proliferation, and its dysregulation is associated with both cancer and neurodegenerative diseases, making CK1δ an attractive therapeutic target. This study aimed to develop novel CK1δ inhibitors with favourable drug-like properties through the synthesis and biological evaluation of benzimidazol-2-acetamide derivatives. Methods: A novel series of benzimidazol-2-acetamide derivatives was synthesized, incorporating different substituents on the benzimidazole core (5-chloro, 5,6-dichloro, 5-nitro, and 5-cyano) and various saturated cyclic amines on the acetamide moiety. Compounds were evaluated for CK1δ inhibitory activity, while molecular docking and molecular dynamics simulations were performed to investigate their binding mode. In silico ADME predictions assessed pharmacokinetic properties, and cytotoxicity was evaluated in SH-SY5Y neuroblastoma cells. Results: The 5,6-dichloro derivatives 20 and 24, bearing piperidin-4-ylmethanamine and morpholine moieties, respectively, displayed the highest CK1δ inhibitory activity (IC₅₀ = 0.172 and 0.223 μM). The 5-cyano analogue 22 also exhibited a good potency (IC₅₀ = 0.224 μM). Computational studies confirmed an ATP-competitive binding mode and highlighted the dynamic behaviour of the solvent-exposed substituents within the CK1δ binding site. Predicted pharmacokinetic properties suggested favourable oral absorption and blood-brain barrier penetration. Compounds 20, 22, and 24 showed no cytotoxicity in SH-SY5Y cells at concentrations up to 10 μM. Conclusions: The new benzimidazol-2-acetamide derivatives exhibited good inhibitor activity against CK1δ, favourable predicted ADME properties, and low cellular toxicity. The combined experimental and computational findings provide valuable insights for the further optimization of this scaffold toward the development of therapeutics for CK1δ-related diseases.
SN - 1424-8247
ER -